← 產業報告目錄

Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Machinery & Equipment出版日期 2026-07-03頁數 732報告編號 BT2120

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global biomarkers market is expected to reach USD 112.10 billion by 2031 from USD 67.95 billion in 2026, at a CAGR of 10.5% from 2026 to 2031. This growth is driven by the increasing integration of artificial intelligence, digital pathology, and bioinformatics, as well as the rising adoption of precision medicine and companion diagnostics. In 2025, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market. The biomarkers market is categorized by type into three segments: safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further divided into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, predictive biomarkers accounted for the largest share globally in the efficacy biomarkers segment. This dominance is primarily due to their crucial role in facilitating personalized treatment by identifying patients most likely to respond to specific therapies. This capability ultimately improves treatment outcomes and enhances clinical decision-making. The use of predictive biomarkers has gained significant traction in fields such as oncology, autoimmune diseases, and infectious diseases. Additionally, the increasing number of companion diagnostic approvals for predictive biomarkers is driving market adoption. For instance, in June 2026, the FDA approved Roche’s first companion diagnostic to assess the PTEN protein in prostate cancer. The VENTANA PTEN assay enables the identification of patients eligible for more targeted treatment decisions. By technology, the immunoassays segment held the largest share of the biomarkers market in 2025. The biomarkers market is divided into several technologies, including immunoassays, NGS (next-generation sequencing), PCR (polymerase chain reaction), mass spectrometry, chromatography, and others. In 2025, immunoassays are expected to hold the largest share of the biomarker market due to their high specificity and ability to detect a wide range of biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Immunoassays are favored for biomarker detection because they are compatible with both clinical diagnostics and research applications. Additionally, their scalability and automation capabilities enable high-throughput testing, which is essential for meeting the increasing demand for precision diagnostics. Major companies are actively enhancing their immunoassay platforms to improve their diagnostic offerings. For instance, Roche provides the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott is expanding its ARCHITECT and Alinity immunoassay systems to test for infectious diseases and monitor chronic conditions. APAC is the fastest-growing regional segment in the global biomarkers market from 2026 to 2031. The biomarkers market is divided into several regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to experience the highest CAGR during the forecast period. This growth is primarily driven by the expanding healthcare infrastructure in countries such as China, India, and Japan, along with increasing investments in precision medicine, genomic research, and diagnostic innovation. The rising prevalence of chronic diseases, including cancer, cardiovascular disorders, metabolic diseases, and infectious diseases, is accelerating the demand for biomarker-based diagnostics and personalized treatment approaches. Additionally, the growth of clinical trial activities, the increasing adoption of companion diagnostics, supportive government initiatives for biotechnology and life sciences research, and the rapid integration of genomics, proteomics, and AI-enabled analytics are all contributing to the regional market growth. Furthermore, expanding local biopharmaceutical manufacturing capabilities and improving regulatory frameworks are enhancing commercialization opportunities, establishing the Asia Pacific region as a significant hub for growth and innovation in the biomarkers market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (70%) and Demand Side (30%) • By Designation: Managers (45%), CXO and Directors (30%), and Executives (25%) • By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) List of Companies Profiled in the Report F. Hoffmann-La Roche Ltd. (Switzerland) Merck KGaA (Germany) Abbott (US) Thermo Fisher Scientific, Inc. (US) QIAGEN (Germany) Charles River Laboratories (US) Eurofins Scientific (Luxembourg) LabCorp (US) Revvity (US) bioMérieux (France) Guardant Health (US) JSR Corporation (Crown Biosciences) (Japan) Agilent Technologies, Inc. (US) Bio-Rad Laboratories (US) Illumina, Inc. (US) Quanterix (US) Meso Scale Diagnostics, LLC (US) Intertek Group Plc (UK) Meridian Bioscience (US) BioAgilytix Labs (US) R-Biopharm AG (Germany) Enzo Biochem (US) WuXi AppTec (China) Standard BioTools (US) Diatech Pharmacogenetics (Italy) Synexa Life Sciences BV (Netherlands) Proteome Sciences (UK) Pillar Biosciences (US) StressMarq Biosciences Inc. (Canada) Sebia (France) Bio-Techne (US) C2N Diagnostics (US) NorthEast Bioanalytical Laboratories (US) Signosis (US) Myriad Genetics, Inc. (US) Research Coverage: This research report categorizes the global biomarkers market by offering, type, research area, technology, disease indication, and end user. The report provides comprehensive information about the key factors influencing the growth of the biomarkers market, including drivers, restraints, challenges, and opportunities. It also includes a detailed analysis of major industry players, offering insights into their business overviews, products, solutions, key strategies, collaborations, partnerships, and agreements. Additionally, the report covers new approvals and product launches, as well as recent collaborations, acquisitions, and developments within the global biomarkers market. Key Benefits of Buying the Report: The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (rising adoption of precision medicine and companion diagnostics, growing use of NGS, PCR, proteomics, and multi-omics platforms, increasing biomarker use in drug discovery and clinical trial design, rising burden of cancer, cardiovascular, neurological, and infectious diseases, expansion of liquid biopsy and minimally invasive biomarker testing, and increasing integration of AI, digital pathology, and bioinformatics), restraints (high cost of advanced biomarker discovery and validation and complex regulatory and reimbursement pathways), opportunities (co-development of biomarkers with targeted therapies and immunotherapies, expansion of blood-based biomarkers for oncology and neurology, growth in proteomics, spatial biology, and multi-omics biomarker discovery, and rising outsourcing of biomarker assay development and validation), and challenges (translating discovery biomarkers into clinically validated tests and patient heterogeneity and disease complexity) • Product Development/Innovation: Detailed insights on upcoming technologies and research & development activities in the global biomarkers market • Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions. • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global biomarkers market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been conducted to provide insights into their strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics for the global biomarkers market.
目錄 Table of Contents
1 INTRODUCTION 56 1.1 STUDY OBJECTIVES 56 1.2 MARKET DEFINITION 56 1.3 STUDY SCOPE 56 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 57 1.3.2 INCLUSIONS & EXCLUSIONS 58 1.3.3 YEARS CONSIDERED 59 1.4 CURRENCY CONSIDERED 59 1.5 STAKEHOLDERS 59 1.6 SUMMARY OF CHANGES 60 2 EXECUTIVE SUMMARY 61 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 61 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 63 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 64 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 65 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 66 3 PREMIUM INSIGHTS 67 3.1 BIOMARKERS MARKET OVERVIEW 67 3.2 BIOMARKERS MARKET, BY TYPE & REGION 68 3.3 BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT 70 4 MARKET OVERVIEW 71 4.1 INTRODUCTION 71 4.2 MARKET DYNAMICS 71 4.2.1 DRIVERS 73 4.2.1.1 Rising adoption of precision medicine and companion diagnostics 73 4.2.1.2 Growing use of NGS, PCR, proteomics, and multi-omics platforms 73 4.2.1.3 Increasing biomarker use in drug discovery and clinical trial design 73 4.2.1.4 Rising burden of cancer, cardiovascular, neurological, and infectious diseases 74 4.2.1.5 Expansion of liquid biopsy and minimally invasive biomarker testing 74 4.2.1.6 Increasing integration of AI, digital pathology, and bioinformatics 74 4.2.2 RESTRAINTS 75 4.2.2.1 High cost of advanced biomarker discovery and validation 75 4.2.2.2 Complex regulatory and reimbursement pathways 75 4.2.3 OPPORTUNITIES 75 4.2.3.1 Co-development of biomarkers with targeted therapies and immunotherapies 75 4.2.3.2 Expansion of blood-based biomarkers for oncology and neurology 75 4.2.3.3 Growth in proteomics, spatial biology, and multi-omics biomarker discovery 76 4.2.3.4 Rising outsourcing of biomarker assay development and validation 76 4.2.4 CHALLENGES 76 4.2.4.1 Patient heterogeneity and disease complexity 76 4.2.4.2 Translating discovery biomarkers into clinically validated tests 77 4.3 UNMET NEEDS & WHITE SPACES 77 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 78 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 79 5 INDUSTRY TRENDS 80 5.1 PORTER’S FIVE FORCES ANALYSIS 80 5.1.1 THREAT OF NEW ENTRANTS 81 5.1.2 THREAT OF SUBSTITUTES 81 5.1.3 BARGAINING POWER OF BUYERS 81 5.1.4 BARGAINING POWER OF SUPPLIERS 81 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81 5.2 MACROECONOMIC OUTLOOK 82 5.2.1 INTRODUCTION 82 5.2.2 GDP TRENDS & FORECAST 82 5.2.3 TRENDS IN GLOBAL BIOMARKERS MARKET 83 5.3 SUPPLY CHAIN ANALYSIS 83 5.4 VALUE CHAIN ANALYSIS 84 5.5 ECOSYSTEM ANALYSIS 86 5.6 PRICING ANALYSIS 87 5.6.1 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 87 5.6.2 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 89 5.7 TRADE ANALYSIS 90 5.7.1 IMPORT DATA 90 5.7.2 EXPORT DATA 91 5.7.3 IMPORT VOLUME 92 5.7.4 EXPORT VOLUME 92 5.8 KEY CONFERENCES & EVENTS, 2026–2027 93 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94 5.10 INVESTMENT/FUNDING ACTIVITY 94 5.11 CASE STUDY ANALYSIS 95 5.12 IMPACT OF 2025 US TARIFFS ON BIOMARKERS MARKET 97 5.12.1 INTRODUCTION 97 5.12.2 KEY TARIFF RATES 97 5.12.3 PRICE IMPACT ANALYSIS 98 5.12.4 IMPACT ON COUNTRY/REGION 98 5.12.4.1 North America 98 5.12.4.2 Europe 99 5.12.4.3 Asia Pacific 99 5.12.5 IMPACT ON END-USE INDUSTRIES 100 5.12.5.1 Pharmaceutical & biotechnology companies 100 5.12.5.2 Hospitals & diagnostic laboratories 100 5.12.5.3 Academic & research institutes 101 5.12.5.4 Other end users 101 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 102 6.1 TECHNOLOGY ANALYSIS 102 6.1.1 KEY TECHNOLOGIES 102 6.1.1.1 Immunoassays 102 6.1.1.2 Next-generation sequencing (NGS) 102 6.1.1.3 Polymerase chain reaction (PCR) 102 6.1.1.4 In situ hybridization 103 6.1.1.5 Microarrays 103 6.1.1.6 Mass spectrometry 103 6.1.2 ADJACENT TECHNOLOGIES 104 6.1.2.1 Artificial intelligence (AI) and machine learning (ML) 104 6.1.2.2 Sensors (wearable devices) 104 6.1.3 COMPLEMENTARY TECHNOLOGIES 104 6.1.3.1 Liquid biopsy 104 6.1.3.2 CRISPR 104 6.2 TECHNOLOGY/PRODUCT ROADMAP 105 6.3 PATENT ANALYSIS 105 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015–2025 106 6.4 FUTURE APPLICATIONS 107 6.5 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET 108 6.5.1 TOP USE CASES & MARKET POTENTIAL 109 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET 110 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 110 6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET 111 6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS 112 7 SUSTAINABILITY & REGULATORY LANDSCAPE 113 7.1 REGIONAL REGULATIONS & COMPLIANCE 113 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113 7.1.2 REGULATORY FRAMEWORK 120 7.1.3 INDUSTRY STANDARDS 122 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 123 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 123 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 125 8.1 DECISION-MAKING PROCESS 125 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 126 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 126 8.2.2 KEY BUYING CRITERIA, BY END USER 127 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 128 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 128 8.5 MARKET PROFITABILITY 129 9 BIOMARKERS MARKET, BY OFFERING 130 9.1 INTRODUCTION 131 9.2 CONSUMABLES 131 9.2.1 ASSAY KITS 135 9.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth 135 9.2.2 REAGENTS & CHEMICALS 139 9.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand 139 9.2.3 OTHER CONSUMABLES 143 9.3 SERVICES 147 9.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION 147 9.4 SOFTWARE 152 9.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH 152 10 BIOMARKERS MARKET, BY TYPE 156 10.1 INTRODUCTION 157 10.2 SAFETY BIOMARKERS 157 10.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS & DEVELOPMENT TO BOOST MARKET GROWTH 157 10.3 EFFICACY BIOMARKERS 161 10.3.1 PREDICTIVE BIOMARKERS 165 10.3.1.1 Rising applications of biomarkers in personalized medicine to drive market 165 10.3.2 SURROGATE BIOMARKERS 169 10.3.2.1 Ability to serve as reliable indicators in place of clinical endpoints to support market growth 169 10.3.3 PHARMACODYNAMIC BIOMARKERS 173 10.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market 173 10.3.4 PROGNOSTIC BIOMARKERS 177 10.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers 177 10.4 VALIDATION BIOMARKERS 181 10.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH 181 11 BIOMARKERS MARKET, BY RESEARCH AREA 185 11.1 INTRODUCTION 186 11.2 GENOMICS 187 11.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH 187 11.3 PROTEOMICS 191 11.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND 191 11.4 METABOLOMICS 195 11.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH 195 11.5 OTHER RESEARCH AREAS 198 12 BIOMARKERS MARKET, BY TECHNOLOGY 203 12.1 INTRODUCTION 204 12.2 IMMUNOASSAYS 204 12.2.1 ELISA 209 12.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth 209 12.2.2 PROTEIN MICROARRAYS 213 12.2.2.1 Quick and cost-effective nature of technology to support growth 213 12.2.3 WESTERN BLOT 216 12.2.3.1 Increasing investments in proteomics research to drive market 216 12.3 NEXT-GENERATION SEQUENCING (NGS) 220 12.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH 220 12.4 POLYMERASE CHAIN REACTION (PCR) 224 12.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET 224 12.5 MASS SPECTROMETRY 228 12.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH 228 12.6 CHROMATOGRAPHY 232 12.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH 232 12.7 OTHER TECHNOLOGIES 235 13 BIOMARKERS MARKET, BY APPLICATION 240 13.1 INTRODUCTION 241 13.2 CLINICAL DIAGNOSTICS 241 13.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND 241 13.3 DRUG DISCOVERY & DEVELOPMENT 245 13.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH 245 13.4 PERSONALIZED MEDICINE 250 13.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND 250 13.5 CLINICAL RESEARCH 254 13.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET 254 13.6 OTHER APPLICATIONS 257 14 BIOMARKERS MARKET, BY DISEASE INDICATION 262 14.1 INTRODUCTION 263 14.2 CANCER 263 14.2.1 BREAST CANCER 269 14.2.1.1 Expanding precision oncology and companion diagnostics to drive global growth in breast cancer biomarkers 269 14.2.2 LUNG CANCER 272 14.2.2.1 Expanding targeted therapies and rapid molecular profiling to drive global growth in lung cancer biomarkers 272 14.2.3 COLORECTAL CANCER 276 14.2.3.1 Expanding RAS/BRAF testing, liquid biopsy, and biomarker-linked targeted therapies to drive global 276 14.2.4 PROSTATE CANCER 279 14.2.4.1 Growth in HRR, PTEN, and liquid biopsy testing to accelerate biomarker adoption 279 14.2.5 HEMATOLOGICAL CANCER 283 14.2.5.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers 283 14.2.6 OTHER CANCERS 286 14.3 INFECTIOUS DISEASES 290 14.3.1 HIV/AIDS 294 14.3.1.1 Expanding self-testing and viral load monitoring to drive global growth 294 14.3.2 HEPATITIS (B & C) 298 14.3.2.1 Rising hepatitis screening and automated immunoassay adoption to drive growth of HBV and HCV biomarkers 298 14.3.3 RESPIRATORY INFECTIONS 301 14.3.3.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers 301 14.3.4 OTHER INFECTIOUS DISEASES 305 14.4 IMMUNOLOGICAL DISORDERS 308 14.4.1 RHEUMATOID ARTHRITIS 313 14.4.1.1 Earlier diagnosis and therapy-response stratification to drive growth in rheumatoid arthritis biomarkers 313 14.4.2 INFLAMMATORY BOWEL DISEASE 316 14.4.2.1 Non-invasive inflammation monitoring and targeted therapy management to drive growth in IBD biomarkers 316 14.4.3 OTHER IMMUNOLOGICAL DISORDERS 320 14.5 NEUROLOGICAL DISORDERS 323 14.5.1 ALZHEIMER’S DISEASE 328 14.5.1.1 Growing demand for less-invasive alternatives to PET imaging and cerebrospinal fluid testing to boost market growth 328 14.5.2 PARKINSON’S DISEASE 331 14.5.2.1 Alpha-synuclein and digital biomarker advances to drive growth in Parkinson’s disease biomarkers 331 14.5.3 MULTIPLE SCLEROSIS 335 14.5.3.1 Blood-based neurofilament light chain testing to strengthen growth in multiple sclerosis biomarkers 335 14.5.4 OTHER NEUROLOGICAL DISORDERS 338 14.6 METABOLIC & ENDOCRINE DISORDERS 341 14.6.1 DIABETES 345 14.6.1.1 Continuous glucose-ketone monitoring and connected diabetes care to drive growth in diabetes biomarkers 345 14.6.2 OBESITY 349 14.6.2.1 GLP-1 therapy expansion and payer demand for response prediction to drive growth in obesity biomarkers 349 14.6.3 OTHER METABOLIC & ENDOCRINE DISORDERS 352 14.7 CARDIOVASCULAR DISORDERS 356 14.7.1 CONTINUOUS INNOVATION IN CARDIAC BIOMARKERS TO BOOST MARKET GROWTH 356 14.8 OTHER DISEASE INDICATIONS 360 15 BIOMARKERS MARKET, BY END USER 364 15.1 INTRODUCTION 365 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 365 15.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH 365 15.3 HOSPITALS & DIAGNOSTIC LABORATORIES 369 15.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH 369 15.4 ACADEMIC & RESEARCH INSTITUTES 373 15.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET 373 15.5 OTHER END USERS 376 16 BIOMARKERS MARKET, BY REGION 381 16.1 INTRODUCTION 382 16.2 NORTH AMERICA 382 16.2.1 US 391 16.2.1.1 Rising focus on biopharma research to support growth 391 16.2.2 CANADA 398 16.2.2.1 Increasing incidence of cancer to drive biomarkers market growth 398 16.3 EUROPE 405 16.3.1 GERMANY 414 16.3.1.1 Growth in biopharmaceutical R&D activities to propel growth 414 16.3.2 UK 422 16.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 422 16.3.3 FRANCE 429 16.3.3.1 Increasing government investment for proteomics & genomics research to drive growth 429 16.3.4 ITALY 436 16.3.4.1 Increasing developments in life science research to fuel growth 436 16.3.5 SPAIN 443 16.3.5.1 R&D initiatives for personalized medicine to support market growth 443 16.3.6 REST OF EUROPE 450 16.4 ASIA PACIFIC 458 16.4.1 CHINA 468 16.4.1.1 Rising incidence of CVD to propel market 468 16.4.2 JAPAN 474 16.4.2.1 Strong regulatory guidelines for drug discovery & development to support market growth 474 16.4.3 INDIA 481 16.4.3.1 Favorable scenario for FDI and increasing number of clinical trials to propel market 481 16.4.4 SOUTH KOREA 489 16.4.4.1 Increasing innovations in NGS technologies to support market growth 489 16.4.5 AUSTRALIA 495 16.4.5.1 Increasing demand for diagnostic solutions to propel market 495 16.4.6 REST OF ASIA PACIFIC 502 16.5 LATIN AMERICA 509 16.5.1 BRAZIL 517 16.5.1.1 Increased government investments in pharmaceutical R&D to drive market 517 16.5.2 MEXICO 524 16.5.2.1 Rising demand for chronic disease treatment to support market growth 524 16.5.3 REST OF LATIN AMERICA 531 16.6 MIDDLE EAST 538 16.6.1 GCC COUNTRIES 545 16.6.1.1 Saudi Arabia 553 16.6.1.1.1 Growing healthcare expenditure to boost market growth 553 16.6.1.2 UAE 560 16.6.1.2.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth 560 16.6.1.3 Rest of GCC countries 567 16.6.2 REST OF MIDDLE EAST 574 16.7 AFRICA 581 16.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 581 17 COMPETITIVE LANDSCAPE 589 17.1 OVERVIEW 589 17.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023−2026 589 17.3 REVENUE ANALYSIS, 2023–2025 590 17.4 MARKET SHARE ANALYSIS, 2025 591 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 594 17.5.1 STARS 594 17.5.2 EMERGING LEADERS 594 17.5.3 PERVASIVE PLAYERS 594 17.5.4 PARTICIPANTS 594 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 596 17.5.5.1 Company footprint 596 17.5.5.2 Region footprint 597 17.5.5.3 Offering footprint 598 17.5.5.4 Technology footprint 599 17.5.5.5 Application footprint 601 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 602 17.6.1 PROGRESSIVE COMPANIES 602 17.6.2 RESPONSIVE COMPANIES 602 17.6.3 DYNAMIC COMPANIES 602 17.6.4 STARTING BLOCKS 602 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 604 17.6.5.1 Detailed list of key startups/SME players 604 17.6.5.2 Competitive benchmarking of key startups/SME players 605 17.7 COMPANY VALUATION & FINANCIAL METRICS 606 17.7.1 FINANCIAL METRICS 606 17.7.2 COMPANY VALUATION 606 17.8 BRAND/PRODUCT COMPARISON 607 17.9 COMPETITIVE SCENARIO 608 17.9.1 PRODUCT LAUNCHES & APPROVALS 608 17.9.2 DEALS 609 17.9.3 EXPANSIONS 610 18 COMPANY PROFILES 611 18.1 KEY PLAYERS 611 18.1.1 F. HOFFMANN-LA ROCHE LTD. 611 18.1.1.1 Business overview 611 18.1.1.2 Products & services offered 612 18.1.1.3 Recent developments 615 18.1.1.3.1 Product launches & approvals 615 18.1.1.3.2 Deals 617 18.1.1.4 MnM view 617 18.1.1.4.1 Right to win 617 18.1.1.4.2 Strategic choices 617 18.1.1.4.3 Weaknesses & competitive threats 618 18.1.2 DANAHER CORPORATION 619 18.1.2.1 Business overview 619 18.1.2.2 Products offered 620 18.1.2.3 MnM view 621 18.1.2.3.1 Right to win 621 18.1.2.3.2 Strategic choices 622 18.1.2.3.3 Weaknesses & competitive threats 622 18.1.3 ILLUMINA, INC. 623 18.1.3.1 Business overview 623 18.1.3.2 Products & services offered 624 18.1.3.3 Recent developments 625 18.1.3.3.1 Product launches & approvals 625 18.1.3.3.2 Deals 625 18.1.3.4 MnM view 625 18.1.3.4.1 Right to win 625 18.1.3.4.2 Strategic choices 626 18.1.3.4.3 Weaknesses & competitive threats 626 18.1.4 MERCK KGAA 627 18.1.4.1 Business overview 627 18.1.4.2 Products & services offered 628 18.1.4.3 Recent developments 632 18.1.4.3.1 Deals 632 18.1.4.3.2 Expansions 633 18.1.4.4 MnM view 633 18.1.4.4.1 Right to win 633 18.1.4.4.2 Strategic choices 633 18.1.4.4.3 Weaknesses & competitive threats 633 18.1.5 THERMO FISHER SCIENTIFIC INC. 634 18.1.5.1 Business overview 634 18.1.5.2 Products & services offered 635 18.1.5.3 Recent developments 641 18.1.5.3.1 Product approvals 641 18.1.5.3.2 Deals 641 18.1.5.3.3 Expansions 643 18.1.5.4 MnM view 643 18.1.5.4.1 Right to win 643 18.1.5.4.2 Strategic choices 643 18.1.5.4.3 Weaknesses & competitive threats 644 18.1.6 QIAGEN 645 18.1.6.1 Business overview 645 18.1.6.2 Products & services offered 646 18.1.6.3 Recent developments 649 18.1.6.3.1 Product launches 649 18.1.6.3.2 Deals 649 18.1.6.3.3 Expansions 650 18.1.7 ABBOTT 651 18.1.7.1 Business overview 651 18.1.7.2 Products & services offered 652 18.1.7.3 Recent developments 654 18.1.7.3.1 Product approvals 654 18.1.7.3.2 Deals 654 18.1.8 AGILENT TECHNOLOGIES, INC. 655 18.1.8.1 Business overview 655 18.1.8.2 Products & services offered 656 18.1.8.3 Recent developments 657 18.1.8.3.1 Product approvals 657 18.1.8.3.2 Deals 659 18.1.9 REVVITY INC. 660 18.1.9.1 Business overview 660 18.1.9.2 Products & services offered 661 18.1.9.3 Recent developments 662 18.1.9.3.1 Product launches 662 18.1.10 CHARLES RIVER LABORATORIES 663 18.1.10.1 Business overview 663 18.1.10.2 Products & services offered 664 18.1.10.3 Recent developments 665 18.1.10.3.1 Deals 665 18.1.11 BIO-RAD LABORATORIES, INC. 666 18.1.11.1 Business overview 666 18.1.11.2 Products & services offered 667 18.1.11.3 Recent developments 668 18.1.11.3.1 Product launches 668 18.1.11.3.2 Deals 669 18.1.12 EUROFINS SCIENTIFIC 670 18.1.12.1 Business overview 670 18.1.12.2 Products & services offered 671 18.1.12.3 Recent developments 672 18.1.12.3.1 Deals 672 18.1.13 BIOMÉRIEUX 673 18.1.13.1 Business overview 673 18.1.13.2 Products & services offered 674 18.1.13.3 Recent developments 675 18.1.13.3.1 Product approvals 675 18.1.13.3.2 Deals 675 18.1.13.3.3 Expansions 676 18.1.14 JSR CORPORATION 677 18.1.14.1 Business overview 677 18.1.14.2 Products & services offered 678 18.1.14.3 Recent developments 679 18.1.14.3.1 Deals 679 18.1.15 GUARDANT HEALTH 680 18.1.15.1 Business overview 680 18.1.15.2 Products & services offered 681 18.1.15.3 Recent developments 682 18.1.15.3.1 Product approvals 682 18.1.15.3.2 Deals 682 18.1.16 LABCORP 685 18.1.16.1 Business overview 685 18.1.16.2 Products & services offered 686 18.1.16.3 Recent developments 687 18.1.16.3.1 Product launches 687 18.1.17 QUANTERIX 688 18.1.17.1 Business overview 688 18.1.17.2 Products & services offered 689 18.1.17.3 Recent developments 690 18.1.17.3.1 Product launches 690 18.1.17.3.2 Deals 690 18.1.18 MESO SCALE DIAGNOSTICS, LLC 691 18.1.18.1 Business overview 691 18.1.18.2 Products & services offered 691 18.1.19 SIEMENS HEALTHINEERS AG 693 18.1.19.1 Business overview 693 18.1.19.2 Products offered 694 18.2 OTHER PLAYERS 696 18.2.1 CELERION 696 18.2.2 STANDARD BIOTOOLS 697 18.2.3 SEBIA 698 18.2.4 BIOAGILYTIX LABS 699 18.2.5 STRESSMARQ BIOSCIENCES INC. 700 18.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC 701 18.2.7 SIGNOSIS 702 18.2.8 SERIMMUNE 703 18.2.9 THERAINDX LIFESCIENCES PVT. LTD. 703 18.2.10 SYNEXA LIFE SCIENCES BV 704 18.2.11 DIATECH PHARMACOGENETICS 705 18.2.12 PILLAR BIOSCIENCES 706 18.2.13 R-BIOPHARM AG 707 19 RESEARCH METHODOLOGY 708 19.1 RESEARCH DATA 708 19.1.1 SECONDARY DATA 709 19.1.2 PRIMARY DATA 710 19.2 MARKET ESTIMATION METHODOLOGY 711 19.2.1 INSIGHTS OF PRIMARY EXPERTS 714 19.2.2 TOP-DOWN APPROACH 715 19.3 MARKET GROWTH RATE FORECAST 716 19.4 MARKET BREAKDOWN & DATA TRIANGULATION 717 19.5 RESEARCH ASSUMPTIONS 719 19.6 RESEARCH LIMITATIONS 719 19.7 RISK ASSESSMENT 720 20 APPENDIX 721 20.1 DISCUSSION GUIDE 721 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 727 20.3 CUSTOMIZATION OPTIONS 729 20.4 RELATED REPORTS 729 20.5 AUTHOR DETAILS 730
圖表清單 List of Tables & Figures
TABLE 1 BIOMARKERS MARKET: IMPACT ANALYSIS 72 TABLE 2 BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 80 TABLE 3 BIOMARKERS MARKET: ROLE IN ECOSYSTEM 86 TABLE 4 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 (USD) 88 TABLE 5 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 89 TABLE 6 IMPORT DATA FOR HS CODE 382219, 2022–2025, (USD THOUSAND) 90 TABLE 7 EXPORT DATA HS CODE 382200, 2022–2025, (USD THOUSAND) 91 TABLE 8 IMPORT VOLUME HS CODE 382219, 2022–2025 (TONS) 92 TABLE 9 EXPORT VOLUME HS CODE 382219, 2022–2025 (TONS) 92 TABLE 10 BIOMARKERS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 93 TABLE 11 CASE STUDY 1: ADVANCED GENOMIC PROFILING TO SUPPORT PRECISION ONCOLOGY ADOPTION 95 TABLE 12 CASE STUDY 2: EXPANSION OF LIQUID BIOPSY ACCESS FOR MINIMALLY INVASIVE CANCER BIOMARKER TESTING 96 TABLE 13 CASE STUDY 3: POPULATION PROTEOMICS EXPANSION TO ACCELERATE BIOMARKER DISCOVERY 96 TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 97 TABLE 15 INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2025 107 TABLE 16 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET 110 TABLE 17 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET 111 TABLE 18 KEY SUCCESS STORIES WITH RESPECT TO REAL-WORLD APPLICATIONS IN BIOMARKERS MARKET 112 TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114 TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115 TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117 TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119 TABLE 23 COUNTRY-WISE REGULATORY SCENARIO FOR BIOMARKER-BASED PRODUCT & SERVICE PROVIDERS 121 TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 126 TABLE 25 KEY BUYING CRITERIA, BY END USER 127 TABLE 26 BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 131 TABLE 27 BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 28 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 29 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 30 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 31 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 32 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 33 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 34 BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 135 TABLE 35 BIOMARKER ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 36 NORTH AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 37 EUROPE: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 38 ASIA PACIFIC: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 39 LATIN AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 40 MIDDLE EAST: BIOMARKER ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 41 GCC COUNTRIES: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 42 BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 43 NORTH AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 44 EUROPE: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 45 ASIA PACIFIC: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 46 LATIN AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 47 MIDDLE EAST: BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 48 GCC COUNTRIES: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 49 OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 50 NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 51 EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 52 ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 53 LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 54 MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 55 GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 56 BIOMARKER SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 57 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 58 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 59 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 60 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 61 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 62 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 63 BIOMARKER SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 64 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 65 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 66 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 67 LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 68 MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 69 GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 70 BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 157 TABLE 71 SAFETY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 72 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 73 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 74 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 75 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 76 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 77 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 78 EFFICACY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 79 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162 TABLE 80 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 81 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 82 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 83 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 84 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 85 EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 86 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 87 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 88 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 89 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 90 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 91 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 92 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 93 SURROGATE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 94 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 95 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 96 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 97 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 98 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 99 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 100 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 174 TABLE 101 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 102 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 103 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 104 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 105 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 177 TABLE 106 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 107 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 108 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 109 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 110 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 111 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 112 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 113 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 114 VALIDATION BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 115 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 116 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 117 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 118 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 119 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 120 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 121 BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 186 TABLE 122 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 123 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 124 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 125 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 126 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 127 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 128 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 129 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2031 (USD MILLION) 192 TABLE 130 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 131 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 132 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 133 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 134 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 135 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 136 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2024–2031 (USD MILLION) 196 TABLE 137 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 138 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 139 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 140 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 141 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 142 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 143 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024–2031 (USD MILLION) 199 TABLE 144 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 145 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 146 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 147 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 148 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024–2031 (USD MILLION) 202 TABLE 149 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 150 BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031(USD MILLION) 204 TABLE 151 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031(USD MILLION) 205 TABLE 152 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 206 TABLE 153 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 206 TABLE 154 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 207 TABLE 155 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 207 TABLE 156 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031(USD MILLION) 208 TABLE 157 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION) 208 TABLE 158 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031(USD MILLION) 209 TABLE 159 BIOMARKERS MARKET FOR ELISA, BY REGION, 2024–2031(USD MILLION) 210 TABLE 160 NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION) 210 TABLE 161 EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION) 211 TABLE 162 ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION) 211 TABLE 163 LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION) 212 TABLE 164 MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION, 2024–2031(USD MILLION) 212 TABLE 165 GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION) 212 TABLE 166 BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2024–2031(USD MILLION) 213 TABLE 167 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 214 TABLE 168 EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 214 TABLE 169 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 215 TABLE 170 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 215 TABLE 171 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2024–2031(USD MILLION) 216 TABLE 172 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION) 216 TABLE 173 BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2024–2031(USD MILLION) 217 TABLE 174 NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 217 TABLE 175 EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 218 TABLE 176 ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 218 TABLE 177 LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 218 TABLE 178 MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2024–2031(USD MILLION) 219 TABLE 179 GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION) 219 TABLE 180 BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031(USD MILLION) 221 TABLE 181 NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION) 221 TABLE 182 EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION) 222 TABLE 183 ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION) 222 TABLE 184 LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION) 223 TABLE 185 MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031(USD MILLION) 223 TABLE 186 GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2024–2031(USD MILLION) 223 TABLE 187 BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031(USD MILLION) 225 TABLE 188 NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION) 225 TABLE 189 EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION) 226 TABLE 190 ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION) 226 TABLE 191 LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION) 227 TABLE 192 MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031(USD MILLION) 227 TABLE 193 GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION) 227 TABLE 194 BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031(USD MILLION) 229 TABLE 195 NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 229 TABLE 196 EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 230 TABLE 197 ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 230 TABLE 198 LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 231 TABLE 199 MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031(USD MILLION) 231 TABLE 200 GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION) 231 TABLE 201 BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024–2031(USD MILLION) 232 TABLE 202 NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 233 TABLE 203 EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 233 TABLE 204 ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 234 TABLE 205 LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 234 TABLE 206 MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024–2031(USD MILLION) 235 TABLE 207 GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION) 235 TABLE 208 BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031(USD MILLION) 236 TABLE 209 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 237 TABLE 210 EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 237 TABLE 211 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 238 TABLE 212 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 238 TABLE 213 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031(USD MILLION) 239 TABLE 214 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION) 239 TABLE 215 BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241 TABLE 216 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 242 TABLE 217 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 243 TABLE 218 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 243 TABLE 219 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 220 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 221 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 245 TABLE 222 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 223 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 247 TABLE 224 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 225 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 226 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 227 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 249 TABLE 228 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 249 TABLE 229 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 249 TABLE 230 LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS 250 TABLE 231 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024–2031 (USD MILLION) 251 TABLE 232 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 233 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 234 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 235 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 236 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024–2031 (USD MILLION) 253 TABLE 237 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 238 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION 254 TABLE 239 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 255 TABLE 240 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 255 TABLE 241 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 242 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 243 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 244 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 257 TABLE 245 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 246 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 258 TABLE 247 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 248 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 259 TABLE 249 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 250 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 251 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 261 TABLE 252 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 253 BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 263 TABLE 254 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE 264 TABLE 255 BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 256 BIOMARKERS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 266 TABLE 257 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 266 TABLE 258 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 267 TABLE 259 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 267 TABLE 260 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 261 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 268 TABLE 262 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 263 BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 269 TABLE 264 NORTH AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 270 TABLE 265 EUROPE: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 270 TABLE 266 ASIA PACIFIC: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 267 LATIN AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 268 MIDDLE EAST: BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 272 TABLE 269 GCC COUNTRIES: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 270 BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 273 TABLE 271 NORTH AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 273 TABLE 272 EUROPE: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 273 ASIA PACIFIC: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 274 TABLE 274 LATIN AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 275 TABLE 275 MIDDLE EAST: BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 275 TABLE 276 GCC COUNTRIES: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 275 TABLE 277 BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 276 TABLE 278 NORTH AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 279 EUROPE: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 280 ASIA PACIFIC: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 278 TABLE 281 LATIN AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 278 TABLE 282 MIDDLE EAST: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 279 TABLE 283 GCC COUNTRIES: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 284 BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 280 TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 286 EUROPE: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 282 TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 291 BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 283 TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 293 EUROPE: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 286 TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 298 BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION) 287 TABLE 299 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 287 TABLE 300 EUROPE: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 288 TABLE 301 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 288 TABLE 302 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 289 TABLE 303 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION) 289 TABLE 304 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 289 TABLE 305 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 306 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 291 TABLE 307 NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 292 TABLE 308 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 292 TABLE 309 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293 TABLE 310 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 293 TABLE 311 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 294 TABLE 312 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 294 TABLE 313 BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024–2031 (USD MILLION) 295 TABLE 314 NORTH AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION) 295 TABLE 315 EUROPE: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 316 ASIA PACIFIC: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 317 LATIN AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION) 297 TABLE 318 MIDDLE EAST: BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024–2031 (USD MILLION) 297 TABLE 319 GCC COUNTRIES: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION) 297 TABLE 320 BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION, 2024–2031 (USD MILLION) 298 TABLE 321 NORTH AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 322 EUROPE: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 323 ASIA PACIFIC: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 324 LATIN AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 325 MIDDLE EAST: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION, 2024–2031 (USD MILLION) 301 TABLE 326 GCC COUNTRIES: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION) 301 TABLE 327 BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 302 TABLE 328 NORTH AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 302 TABLE 329 EUROPE: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 303 TABLE 330 ASIA PACIFIC: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 303 TABLE 331 LATIN AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 304 TABLE 332 MIDDLE EAST: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 304 TABLE 333 GCC COUNTRIES: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 304 TABLE 334 BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 305 TABLE 335 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 306 TABLE 336 EUROPE: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 306 TABLE 337 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 307 TABLE 338 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 307 TABLE 339 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 308 TABLE 340 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 308 TABLE 341 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 309 TABLE 342 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 343 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 310 TABLE 344 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 310 TABLE 345 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 311 TABLE 346 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 311 TABLE 347 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 312 TABLE 348 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 312 TABLE 349 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 312 TABLE 350 BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2024–2031 (USD MILLION) 313 TABLE 351 NORTH AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 314 TABLE 352 EUROPE: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 314 TABLE 353 ASIA PACIFIC: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 315 TABLE 354 LATIN AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 315 TABLE 355 MIDDLE EAST: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2024–2031 (USD MILLION) 316 TABLE 356 GCC COUNTRIES: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 316 TABLE 357 BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2024–2031 (USD MILLION) 317 TABLE 358 NORTH AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 317 TABLE 359 EUROPE: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 318 TABLE 360 ASIA PACIFIC: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 318 TABLE 361 LATIN AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 319 TABLE 362 MIDDLE EAST: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2024–2031 (USD MILLION) 319 TABLE 363 GCC COUNTRIES: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 319 TABLE 364 BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 320 TABLE 365 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 321 TABLE 366 EUROPE: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 321 TABLE 367 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 322 TABLE 368 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 322 TABLE 369 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 323 TABLE 370 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 323 TABLE 371 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 372 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 325 TABLE 373 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 325 TABLE 374 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 326 TABLE 375 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 326 TABLE 376 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 327 TABLE 377 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 327 TABLE 378 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 327 TABLE 379 BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2024–2031 (USD MILLION) 328 TABLE 380 NORTH AMERICA: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 329 TABLE 381 EUROPE: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 329 TABLE 382 ASIA PACIFIC: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 330 TABLE 383 LATIN AMERICA: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 330 TABLE 384 MIDDLE EAST: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2024–2031 (USD MILLION) 331 TABLE 385 GCC COUNTRIES: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 331 TABLE 386 BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2024–2031 (USD MILLION) 332 TABLE 387 NORTH AMERICA: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 332 TABLE 388 EUROPE: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 333 TABLE 389 ASIA PACIFIC: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 333 TABLE 390 LATIN AMERICA: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 334 TABLE 391 MIDDLE EAST: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2024–2031 (USD MILLION) 334 TABLE 392 GCC COUNTRIES: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION) 334 TABLE 393 BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024–2031 (USD MILLION) 335 TABLE 394 NORTH AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 335 TABLE 395 EUROPE: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 336 TABLE 396 ASIA PACIFIC: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 336 TABLE 397 LATIN AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 337 TABLE 398 MIDDLE EAST: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024–2031 (USD MILLION) 337 TABLE 399 GCC COUNTRIES: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 337 TABLE 400 BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 338 TABLE 401 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 339 TABLE 402 EUROPE: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 339 TABLE 403 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 340 TABLE 404 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 340 TABLE 405 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 341 TABLE 406 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 341 TABLE 407 BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 408 BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 342 TABLE 409 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 343 TABLE 410 EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 343 TABLE 411 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 344 TABLE 412 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 344 TABLE 413 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 345 TABLE 414 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 345 TABLE 415 BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION) 346 TABLE 416 NORTH AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 346 TABLE 417 EUROPE: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 347 TABLE 418 ASIA PACIFIC: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 347 TABLE 419 LATIN AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 348 TABLE 420 MIDDLE EAST: BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION) 348 TABLE 421 GCC COUNTRIES: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 348 TABLE 422 BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024–2031 (USD MILLION) 349 TABLE 423 NORTH AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 350 TABLE 424 EUROPE: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 350 TABLE 425 ASIA PACIFIC: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 351 TABLE 426 LATIN AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 351 TABLE 427 MIDDLE EAST: BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024–2031 (USD MILLION) 352 TABLE 428 GCC COUNTRIES: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 352 TABLE 429 BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 353 TABLE 430 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 353 TABLE 431 EUROPE: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 354 TABLE 432 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 354 TABLE 433 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 354 TABLE 434 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION) 355 TABLE 435 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 355 TABLE 436 BIOMARKERS FOR CARDIOVASCULAR DISORDERS 356 TABLE 437 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024–2031 (USD MILLION) 357 TABLE 438 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 357 TABLE 439 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 358 TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 358 TABLE 441 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 359 TABLE 442 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024–2031 (USD MILLION) 359 TABLE 443 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 359 TABLE 444 BIOMARKERS FOR RENAL DISORDERS 360 TABLE 445 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 361 TABLE 446 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 361 TABLE 447 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 362 TABLE 448 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 362 TABLE 449 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 363 TABLE 450 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 363 TABLE 451 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 363 TABLE 452 BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 365 TABLE 453 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 366 TABLE 454 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 367 TABLE 455 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 367 TABLE 456 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 368 TABLE 457 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 368 TABLE 458 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 369 TABLE 459 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 369 TABLE 460 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 370 TABLE 461 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 371 TABLE 462 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 371 TABLE 463 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 372 TABLE 464 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 372 TABLE 465 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 373 TABLE 466 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 373 TABLE 467 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 374 TABLE 468 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 374 TABLE 469 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 375 TABLE 470 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 375 TABLE 471 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 375 TABLE 472 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 376 TABLE 473 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 376 TABLE 474 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 378 TABLE 475 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 378 TABLE 476 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 379 TABLE 477 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 379 TABLE 478 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 380 TABLE 479 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 380 TABLE 480 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 380 TABLE 481 BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 382 TABLE 482 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 383 TABLE 483 NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 384 TABLE 484 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 384 TABLE 485 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 384 TABLE 486 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 487 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 385 TABLE 488 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 386 TABLE 489 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 490 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 387 TABLE 491 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 492 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 493 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 494 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 495 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 496 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 390 TABLE 497 NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 390 TABLE 498 US: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 391 TABLE 499 US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 500 US: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 501 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 502 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 392 TABLE 503 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 393 TABLE 504 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 505 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 394 TABLE 506 US: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 395 TABLE 507 US: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 395 TABLE 508 US: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 509 US: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 396 TABLE 510 US: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 397 TABLE 511 US: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 397 TABLE 512 US: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 398 TABLE 513 CANADA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 399 TABLE 514 CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 515 CANADA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 516 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 517 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 400 TABLE 518 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 401 TABLE 519 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 401 TABLE 520 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 402 TABLE 521 CANADA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 402 TABLE 522 CANADA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 523 CANADA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 524 CANADA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 525 CANADA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 526 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 405 TABLE 527 CANADA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 405 TABLE 528 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 406 TABLE 529 EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 406 TABLE 530 EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 407 TABLE 531 EUROPE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407 TABLE 532 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 408 TABLE 533 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 408 TABLE 534 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 409 TABLE 535 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 409 TABLE 536 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 410 TABLE 537 EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 538 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 539 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 540 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 541 EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 542 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 413 TABLE 543 EUROPE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 413 TABLE 544 GERMANY: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 414 TABLE 545 GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 415 TABLE 546 GERMANY: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415 TABLE 547 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 548 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 416 TABLE 549 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 417 TABLE 550 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 551 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 418 TABLE 552 GERMANY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 553 GERMANY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 554 GERMANY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 555 GERMANY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 420 TABLE 556 GERMANY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 420 TABLE 557 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 421 TABLE 558 GERMANY: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 421 TABLE 559 UK: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 422 TABLE 560 UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 561 UK: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 562 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 563 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 423 TABLE 564 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 424 TABLE 565 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 566 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 425 TABLE 567 UK: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 426 TABLE 568 UK: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 426 TABLE 569 UK: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 427 TABLE 570 UK: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 427 TABLE 571 UK: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 428 TABLE 572 UK: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 428 TABLE 573 UK: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 429 TABLE 574 FRANCE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 430 TABLE 575 FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 576 FRANCE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 577 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 578 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 431 TABLE 579 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 432 TABLE 580 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 432 TABLE 581 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 433 TABLE 582 FRANCE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 433 TABLE 583 FRANCE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 434 TABLE 584 FRANCE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 434 TABLE 585 FRANCE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 435 TABLE 586 FRANCE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 435 TABLE 587 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 436 TABLE 588 FRANCE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 436 TABLE 589 ITALY: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 437 TABLE 590 ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 591 ITALY: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 592 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 438 TABLE 593 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 438 TABLE 594 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 439 TABLE 595 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 439 TABLE 596 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 440 TABLE 597 ITALY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 440 TABLE 598 ITALY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 441 TABLE 599 ITALY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 441 TABLE 600 ITALY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 442 TABLE 601 ITALY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 442 TABLE 602 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 443 TABLE 603 ITALY: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 443 TABLE 604 SPAIN: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 444 TABLE 605 SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 444 TABLE 606 SPAIN: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 445 TABLE 607 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 445 TABLE 608 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 445 TABLE 609 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 446 TABLE 610 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 446 TABLE 611 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 447 TABLE 612 SPAIN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 447 TABLE 613 SPAIN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 614 SPAIN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 615 SPAIN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 616 SPAIN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 617 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 450 TABLE 618 SPAIN: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 450 TABLE 619 REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 451 TABLE 620 REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 451 TABLE 621 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452 TABLE 622 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452 TABLE 623 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 453 TABLE 624 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 453 TABLE 625 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 454 TABLE 626 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 454 TABLE 627 REST OF EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 455 TABLE 628 REST OF EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 455 TABLE 629 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 456 TABLE 630 REST OF EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 456 TABLE 631 REST OF EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 457 TABLE 632 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 457 TABLE 633 REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 458 TABLE 634 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 460 TABLE 635 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 460 TABLE 636 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 461 TABLE 637 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 461 TABLE 638 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 462 TABLE 639 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 462 TABLE 640 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 463 TABLE 641 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 463 TABLE 642 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 464 TABLE 643 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 464 TABLE 644 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 465 TABLE 645 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 465 TABLE 646 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 466 TABLE 647 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 466 TABLE 648 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 467 TABLE 649 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 467 TABLE 650 CHINA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 468 TABLE 651 CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 468 TABLE 652 CHINA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 469 TABLE 653 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 469 TABLE 654 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 469 TABLE 655 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 470 TABLE 656 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 470 TABLE 657 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 471 TABLE 658 CHINA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 471 TABLE 659 CHINA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 472 TABLE 660 CHINA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 472 TABLE 661 CHINA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 473 TABLE 662 CHINA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 473 TABLE 663 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 474 TABLE 664 CHINA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 474 TABLE 665 JAPAN: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 475 TABLE 666 JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 475 TABLE 667 JAPAN: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 476 TABLE 668 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 476 TABLE 669 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 476 TABLE 670 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 477 TABLE 671 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 477 TABLE 672 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 478 TABLE 673 JAPAN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 478 TABLE 674 JAPAN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 479 TABLE 675 JAPAN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 479 TABLE 676 JAPAN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 480 TABLE 677 JAPAN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 480 TABLE 678 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 481 TABLE 679 JAPAN: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 481 TABLE 680 INDIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 482 TABLE 681 INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 482 TABLE 682 INDIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 483 TABLE 683 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 483 TABLE 684 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 483 TABLE 685 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 484 TABLE 686 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 484 TABLE 687 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 485 TABLE 688 INDIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 485 TABLE 689 INDIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 486 TABLE 690 INDIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 486 TABLE 691 INDIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 487 TABLE 692 INDIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 487 TABLE 693 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 488 TABLE 694 INDIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 488 TABLE 695 SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 489 TABLE 696 SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 489 TABLE 697 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 490 TABLE 698 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 490 TABLE 699 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 490 TABLE 700 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 491 TABLE 701 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 491 TABLE 702 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 492 TABLE 703 SOUTH KOREA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 492 TABLE 704 SOUTH KOREA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 493 TABLE 705 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 493 TABLE 706 SOUTH KOREA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 494 TABLE 707 SOUTH KOREA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 494 TABLE 708 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 495 TABLE 709 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 495 TABLE 710 AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 496 TABLE 711 AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 496 TABLE 712 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 496 TABLE 713 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 497 TABLE 714 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 497 TABLE 715 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 498 TABLE 716 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 498 TABLE 717 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 499 TABLE 718 AUSTRALIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 499 TABLE 719 AUSTRALIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 500 TABLE 720 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 500 TABLE 721 AUSTRALIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 500 TABLE 722 AUSTRALIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 501 TABLE 723 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 501 TABLE 724 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 502 TABLE 725 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 503 TABLE 726 REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 503 TABLE 727 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 503 TABLE 728 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 504 TABLE 729 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 504 TABLE 730 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 505 TABLE 731 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 505 TABLE 732 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 506 TABLE 733 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 506 TABLE 734 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 507 TABLE 735 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 507 TABLE 736 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 508 TABLE 737 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 508 TABLE 738 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 509 TABLE 739 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 509 TABLE 740 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 510 TABLE 741 LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 510 TABLE 742 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 510 TABLE 743 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 511 TABLE 744 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 511 TABLE 745 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 512 TABLE 746 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 512 TABLE 747 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 513 TABLE 748 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 513 TABLE 749 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 514 TABLE 750 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 514 TABLE 751 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 515 TABLE 752 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 515 TABLE 753 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 516 TABLE 754 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 516 TABLE 755 LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 517 TABLE 756 BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 518 TABLE 757 BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 518 TABLE 758 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 518 TABLE 759 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 519 TABLE 760 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 519 TABLE 761 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 520 TABLE 762 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 520 TABLE 763 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 521 TABLE 764 BRAZIL: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 521 TABLE 765 BRAZIL: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 522 TABLE 766 BRAZIL: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 522 TABLE 767 BRAZIL: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 523 TABLE 768 BRAZIL: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 523 TABLE 769 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 524 TABLE 770 BRAZIL: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 524 TABLE 771 MEXICO: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 525 TABLE 772 MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 525 TABLE 773 MEXICO: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 526 TABLE 774 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 526 TABLE 775 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 526 TABLE 776 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 527 TABLE 777 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 527 TABLE 778 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 528 TABLE 779 MEXICO: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 528 TABLE 780 MEXICO: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 529 TABLE 781 MEXICO: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 529 TABLE 782 MEXICO: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 530 TABLE 783 MEXICO: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 530 TABLE 784 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 531 TABLE 785 MEXICO: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 531 TABLE 786 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 532 TABLE 787 REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 532 TABLE 788 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 533 TABLE 789 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 533 TABLE 790 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 533 TABLE 791 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 534 TABLE 792 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 534 TABLE 793 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 535 TABLE 794 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 535 TABLE 795 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 536 TABLE 796 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 536 TABLE 797 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 537 TABLE 798 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 537 TABLE 799 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 538 TABLE 800 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 538 TABLE 801 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 539 TABLE 802 MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 539 TABLE 803 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 539 TABLE 804 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 540 TABLE 805 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 540 TABLE 806 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 540 TABLE 807 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 541 TABLE 808 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 541 TABLE 809 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 542 TABLE 810 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 542 TABLE 811 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 543 TABLE 812 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 543 TABLE 813 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 544 TABLE 814 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 544 TABLE 815 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 545 TABLE 816 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 545 TABLE 817 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 546 TABLE 818 GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 546 TABLE 819 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 547 TABLE 820 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 547 TABLE 821 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 547 TABLE 822 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 548 TABLE 823 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 548 TABLE 824 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 549 TABLE 825 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 549 TABLE 826 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 550 TABLE 827 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 550 TABLE 828 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 551 TABLE 829 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 551 TABLE 830 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 552 TABLE 831 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 552 TABLE 832 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 553 TABLE 833 SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 554 TABLE 834 SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 554 TABLE 835 SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 554 TABLE 836 SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 555 TABLE 837 SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 555 TABLE 838 SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 556 TABLE 839 SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 556 TABLE 840 SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 557 TABLE 841 SAUDI ARABIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 557 TABLE 842 SAUDI ARABIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 558 TABLE 843 SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 558 TABLE 844 SAUDI ARABIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 559 TABLE 845 SAUDI ARABIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 559 TABLE 846 SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 560 TABLE 847 SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 560 TABLE 848 UAE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 561 TABLE 849 UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 561 TABLE 850 UAE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 562 TABLE 851 UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 562 TABLE 852 UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 562 TABLE 853 UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 563 TABLE 854 UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 563 TABLE 855 UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 564 TABLE 856 UAE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 564 TABLE 857 UAE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 565 TABLE 858 UAE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 565 TABLE 859 UAE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 565 TABLE 860 UAE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 566 TABLE 861 UAE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 566 TABLE 862 UAE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 567 TABLE 863 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 568 TABLE 864 REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 568 TABLE 865 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 568 TABLE 866 REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 569 TABLE 867 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 569 TABLE 868 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 570 TABLE 869 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 570 TABLE 870 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 571 TABLE 871 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 571 TABLE 872 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 572 TABLE 873 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 572 TABLE 874 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 572 TABLE 875 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 573 TABLE 876 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 573 TABLE 877 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 574 TABLE 878 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 575 TABLE 879 REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 575 TABLE 880 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 575 TABLE 881 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 576 TABLE 882 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 576 TABLE 883 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 577 TABLE 884 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 577 TABLE 885 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 578 TABLE 886 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 578 TABLE 887 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 579 TABLE 888 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 579 TABLE 889 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 579 TABLE 890 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 580 TABLE 891 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 580 TABLE 892 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 581 TABLE 893 AFRICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 581 TABLE 894 AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 582 TABLE 895 AFRICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 582 TABLE 896 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 582 TABLE 897 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION) 583 TABLE 898 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 583 TABLE 899 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION) 584 TABLE 900 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 584 TABLE 901 AFRICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 585 TABLE 902 AFRICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION) 585 TABLE 903 AFRICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 586 TABLE 904 AFRICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 586 TABLE 905 AFRICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION) 587 TABLE 906 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 587 TABLE 907 AFRICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 588 TABLE 908 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOMARKERS MARKET 589 TABLE 909 BIOMARKERS MARKET: DEGREE OF COMPETITION 592 TABLE 910 BIOMARKERS MARKET: REGION FOOTPRINT 597 TABLE 911 BIOMARKERS MARKET: OFFERING FOOTPRINT 598 TABLE 912 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT 599 TABLE 913 BIOMARKERS MARKET: APPLICATION FOOTPRINT 601 TABLE 914 BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 604 TABLE 915 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS 605 TABLE 916 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 608 TABLE 917 BIOMARKERS MARKET: DEALS, JANUARY 2023–JUNE 2026 609 TABLE 918 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2023–JUNE 2026 610 TABLE 919 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 611 TABLE 920 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED 612 TABLE 921 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 615 TABLE 922 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JUNE 2026 617 TABLE 923 DANAHER CORPORATION: COMPANY OVERVIEW 619 TABLE 924 DANAHER CORPORATION: PRODUCTS OFFERED 620 TABLE 925 ILLUMINA, INC.: BUSINESS OVERVIEW 623 TABLE 926 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 624 TABLE 927 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 625 TABLE 928 ILLUMINA, INC.: DEALS, JANUARY 2023—JUNE 2026 625 TABLE 929 MERCK KGAA: BUSINESS OVERVIEW 627 TABLE 930 MERCK KGAA: PRODUCTS & SERVICES OFFERED 628 TABLE 931 MERCK KGAA: DEALS, JANUARY 2023–JUNE 2026 632 TABLE 932 MERCK KGAA: EXPANSIONS, JANUARY 2023–JUNE 2026 633 TABLE 933 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 634 TABLE 934 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 635 TABLE 935 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 641 TABLE 936 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026 641 TABLE 937 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JUNE 2026 643 TABLE 938 QIAGEN: BUSINESS OVERVIEW 645 TABLE 939 QIAGEN: PRODUCTS & SERVICES OFFERED 646 TABLE 940 QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 649 TABLE 941 QIAGEN: DEALS, JANUARY 2023–JUNE 2026 649 TABLE 942 QIAGEN: EXPANSIONS, JANUARY 2023–JUNE 2026 650 TABLE 943 ABBOTT: BUSINESS OVERVIEW 651 TABLE 944 ABBOTT: PRODUCTS & SERVICES OFFERED 652 TABLE 945 ABBOTT: PRODUCT APPROVALS, JANUARY 2023—JUNE 2026 654 TABLE 946 ABBOTT: DEALS, JANUARY 2023—JUNE 2026 654 TABLE 947 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 655 TABLE 948 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 656 TABLE 949 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS, JANUARY 2023—JUNE 2026 657 TABLE 950 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023—JUNE 2026 659 TABLE 951 REVVITY INC.: BUSINESS OVERVIEW 660 TABLE 952 REVVITY INC.: PRODUCTS & SERVICES OFFERED 661 TABLE 953 REVVITY INC.: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 662 TABLE 954 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 663 TABLE 955 CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED 664 TABLE 956 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023—JUNE 2026 665 TABLE 957 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 666 TABLE 958 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 667 TABLE 959 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 668 TABLE 960 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023—JUNE 2026 669 TABLE 961 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 670 TABLE 962 EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED 671 TABLE 963 EUROFINS SCIENTIFIC: DEALS, JANUARY 2023—JUNE 2026 672 TABLE 964 BIOMÉRIEUX: BUSINESS OVERVIEW 673 TABLE 965 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED 674 TABLE 966 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 675 TABLE 967 BIOMÉRIEUX: DEALS, JANUARY 2023—JUNE 2026 675 TABLE 968 BIOMÉRIEUX: EXPANSIONS, JANUARY 2023–JUNE 2026 676 TABLE 969 JSR CORPORATION: BUSINESS OVERVIEW 677 TABLE 970 JSR CORPORATION: PRODUCTS & SERVICES OFFERED 678 TABLE 971 JSR CORPORATION: DEALS, JANUARY 2023—JUNE 2026 679 TABLE 972 GUARDANT HEALTH: BUSINESS OVERVIEW 680 TABLE 973 GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED 681 TABLE 974 GUARDANT HEALTH: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 682 TABLE 975 GUARDANT HEALTH: DEALS, JANUARY 2023—JUNE 2026 682 TABLE 976 LABCORP: BUSINESS OVERVIEW 685 TABLE 977 LABCORP: PRODUCTS & SERVICES OFFERED 686 TABLE 978 LABCORP: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 687 TABLE 979 LABCORP: DEALS, JANUARY 2023—JUNE 2026 687 TABLE 980 QUANTERIX: BUSINESS OVERVIEW 688 TABLE 981 QUANTERIX: PRODUCTS & SERVICES OFFERED 689 TABLE 982 QUANTERIX: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026 690 TABLE 983 QUANTERIX: DEALS, JANUARY 2023—JUNE 2026 690 TABLE 984 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW 691 TABLE 985 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED 691 TABLE 986 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 693 TABLE 987 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 694 TABLE 988 CELERION: COMPANY OVERVIEW 696 TABLE 989 STANDARD BIOTOOLS: COMPANY OVERVIEW 697 TABLE 990 SEBIA: COMPANY OVERVIEW 698 TABLE 991 BIOAGILYTIX LABS: COMPANY OVERVIEW 699 TABLE 992 STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW 700 TABLE 993 NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW 701 TABLE 994 SIGNOSIS: BUSINESS OVERVIEW 702 TABLE 995 SERIMMUNE: BUSINESS OVERVIEW 703 TABLE 996 THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW 703 TABLE 997 SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW 704 TABLE 998 DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW 705 TABLE 999 PILLAR BIOSCIENCES: BUSINESS OVERVIEW 706 TABLE 1000 R-BIOPHARM AG: BUSINESS OVERVIEW 707 FIGURE 1 BIOMARKERS MARKET SEGMENTATION & REGIONAL SCOPE 57 FIGURE 2 BIOMARKERS MARKET: YEARS CONSIDERED 59 FIGURE 3 MARKET SCENARIO 62 FIGURE 4 GLOBAL BIOMARKERS MARKET, 2024–2031 62 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023–2026 63 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF BIOMARKERS MARKET 64 FIGURE 7 HIGH-GROWTH SEGMENTS IN BIOMARKERS MARKET, 2026–2031 65 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOMARKERS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 66 FIGURE 9 RISING ADOPTION OF PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH 67 FIGURE 10 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 68 FIGURE 11 CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 69 FIGURE 12 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 70 FIGURE 13 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71 FIGURE 14 BIOMARKERS MARKET: PORTERS FIVE FORCES ANALYSIS 80 FIGURE 15 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 84 FIGURE 16 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 85 FIGURE 17 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 86 FIGURE 18 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 (USD) 89 FIGURE 19 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 90 FIGURE 20 BIOMARKERS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 94 FIGURE 21 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 95 FIGURE 22 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015–2025 106 FIGURE 23 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET 109 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 126 FIGURE 25 KEY BUYING CRITERIA, BY END USER 127 FIGURE 26 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT 383 FIGURE 27 ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT 459 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2023–2025 (USD MILLION) 591 FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET (2025) 592 FIGURE 30 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 595 FIGURE 31 BIOMARKERS MARKET: COMPANY FOOTPRINT 596 FIGURE 32 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 603 FIGURE 33 EV/EBITDA OF KEY VENDORS 606 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 606 FIGURE 35 BIOMARKERS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 607 FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 612 FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 620 FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 624 FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2025) 628 FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 635 FIGURE 41 QIAGEN: COMPANY SNAPSHOT (2025) 646 FIGURE 42 ABBOTT: COMPANY SNAPSHOT (2025) 652 FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 656 FIGURE 44 REVVITY INC.: COMPANY SNAPSHOT (2025) 661 FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025) 664 FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 667 FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 671 FIGURE 48 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 674 FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024) 678 FIGURE 50 GUARDANT HEALTH: COMPANY SNAPSHOT (2025) 681 FIGURE 51 LABCORP: COMPANY SNAPSHOT (2025) 686 FIGURE 52 QUANTERIX: COMPANY SNAPSHOT (2025) 688 FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025 694 FIGURE 54 RESEARCH DESIGN 708 FIGURE 55 BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 710 FIGURE 56 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 711 FIGURE 57 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 712 FIGURE 58 ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2025) 713 FIGURE 59 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 714 FIGURE 60 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 715 FIGURE 61 BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 716 FIGURE 62 BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 717 FIGURE 63 DATA TRIANGULATION METHODOLOGY 718

同分類最新報告（機械與設備）

查看機械與設備全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們